ENTYVIO 108 mg/.68mL
vedolizumab · INJECTION, SOLUTION · Takeda Pharmaceuticals America, Inc.
No Recall History
Plain English
ENTYVIO is a injection, solution containing vedolizumab at 108 mg/.68mL, taken subcutaneous. Manufactured by Takeda Pharmaceuticals America, Inc..
Key Facts
- Brand Name
- ENTYVIO
- Generic Name
- vedolizumab
- NDC Code (Product)
64764-107- Manufacturer
- Takeda Pharmaceuticals America, Inc.
- Strength
- 108 mg/.68mL
- Dosage Form
- INJECTION, SOLUTION
- Route
- SUBCUTANEOUS
- Marketing Status
- Application #
- BLA761133
- Drug Class
- Integrin Receptor Antagonist [EPC]
- Marketing Start
- 09/27/2023
Recall History
No Recall HistoryFrequently Asked Questions
What is ENTYVIO used for?
ENTYVIO contains vedolizumab. It is a injection, solution taken subcutaneous. Consult your doctor for specific uses.
Is ENTYVIO a controlled substance?
ENTYVIO is not classified as a controlled substance by the DEA.
What is the generic name for ENTYVIO?
The generic name for ENTYVIO is vedolizumab. There are 2 other brand versions of vedolizumab.
What is the NDC code for ENTYVIO 108 mg/.68mL?
The NDC (National Drug Code) for ENTYVIO 108 mg/.68mL is 64764-107, listed by Takeda Pharmaceuticals America, Inc..